Skip to main navigation Investor Relations Site - Hero Circle Menu LEADERSHIP TEAM RESEARCH PIPELINE CORPORATE RESPONSIBILITY FEATURED VIDEOS Events & Presentations NOV 02 2021 at 4:30 PM EDT Vertex Pharmaceuticals Q3 2021 Conference Call READ MORE SEP 15 2021 at 11:00 AM EDT Morgan Stanley Virtual 19th Annual Global Healthcare Conference READ MORE JUL 29 2021 at 5:30 PM EDT Vertex Pharmaceuticals Q2 2021 Conference Call READ MORE VIEW ALL Latest Press Releases NOV 19 2021 Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene READ MORE NOV 12 2021 Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11 READ MORE NOV 02 2021 Vertex Reports Third-Quarter 2021 Financial Results READ MORE VIEW ALL Stock Graph Data Provided by Refinitiv. Minimum 15 minutes delayed. VIEW MORE MICHAEL PARTRIDGE Senior Vice President, Investor Relations +1(617)-341-6108 MANISHA PAI Executive Director, Investor Relations +1(617)-429-6891 MAIN INFO INVESTORINFO@VRTX.COM +1(617)-961-7163 Contacting Vertex's Transfer Agent Communication regarding transfer requirements, lost certificates and changes of address should be directed to: COMPUTERSHARE INVESTOR SERVICES P.O. Box 43023 Providence, RI 02940-3023 Telephone: +1(781)-575-2879 Fax: +1(781)-575-3605 Footer Col 1 NEWS & EVENTS STOCK INFORMATION ANALYST COVERAGE Footer Col 2 FINANCIAL INFORMATION CORPORATE GOVERNANCE INVESTOR RESOURCES Footer Col 3 VERTEX GLOBAL SITES GREAT BRITAIN FRANCE GERMANY SOCIAL MEDIA Privacy Policy Terms of Use Compliance Training Transparency Copyright © 2021